Revenue Growth - Reported fourth quarter 2024 revenue of $7.8 million, a 14% year-over-year increase compared to Q4 2023[4] - Full year 2024 revenue reached $31.4 million, representing a 31% increase over 2023, marking the tenth consecutive year of growth[4] - Overall product revenue, including biologics and drug delivery, grew 76% to $18.6 million for the full year 2024[4] - Biologics and drug delivery revenue increased 27% to $17.3 million for the year ended December 31, 2024[8] - Neurosurgery navigation and therapy revenue increased 21% to $10.3 million for the year ended December 31, 2024[9] - Capital equipment and software revenue increased 107% to $3.8 million for the year ended December 31, 2024[10] - The company estimates 2025 revenue to be between $36.0 million and $41.0 million, representing growth between 15% and 31%[6] Operational Efficiency - Quarterly operational cash burn was $1.2 million, totaling $9.0 million for 2024, a reduction of 35% compared to 2023[4] - Achieved a gross margin of 61% for 2024, up from 57% in 2023[11] - Net cash flows from operating activities improved from $(13,720) million in 2023 to $(8,950) million in 2024, a reduction in cash outflow of approximately 34%[29] - Cash paid for interest decreased from $743 million in 2023 to $480 million in 2024, a reduction of approximately 35%[29] Asset and Liability Management - Total assets decreased from $42,661 million in 2023 to $39,189 million in 2024, a decline of approximately 8.7%[27] - Total current liabilities increased significantly from $7,430 million in 2023 to $10,353 million in 2024, an increase of approximately 39%[27] - Cash and cash equivalents decreased from $23,140 million in 2023 to $20,104 million in 2024, a decline of about 13%[29] - Accounts receivable increased from $3,211 million in 2023 to $4,713 million in 2024, an increase of approximately 47%[27] - Inventory decreased from $7,911 million in 2023 to $6,863 million in 2024, a decline of about 13.2%[27] Equity and Financing - Total stockholders' equity rose from $21,173 million in 2023 to $25,389 million in 2024, an increase of about 19.7%[27] - Proceeds from public offering of common stock amounted to $16,149 million in 2024, contributing positively to financing activities[29] Loss Reduction - Net loss improved from $(22,089) million in 2023 to $(18,914) million in 2024, representing a reduction of about 14%[29] Global Expansion - Activated six new global centers in Q4 2024, totaling 25 new centers for the year, approximately three times the historic activation rate[4]
ClearPoint Neuro(CLPT) - 2024 Q4 - Annual Results